2. Academic Validation
  3. Progress on ocular siRNA gene-silencing therapy and drug delivery systems

Progress on ocular siRNA gene-silencing therapy and drug delivery systems

  • Fundam Clin Pharmacol. 2021 Feb;35(1):4-24. doi: 10.1111/fcp.12561.
Jinjin Jiang 1 2,  Xinru Zhang 1 2,  Yue Tang 1 2,  Shuhan Li 2,  Jing Chen 2
Affiliations

Affiliations

  • 1 State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, No.1, DongQing Road, Guiyang, 550014, People's Republic of China.
  • 2 Department of Pharmacy, China Pharmaceutical University, No.639, Longmian Avenue, Nanjing, 211198, People's Republic of China.
PMID: 32298491 DOI: 10.1111/fcp.12561
Abstract

Age-related macular degeneration (AMD) and glaucoma are global ocular diseases with high blindness rate. RNA interference (RNAi) is being increasingly used in the treatment of these disorders with siRNA drugs, bevasiranib, AGN211745 and PF-04523655 for AMD, and SYL040012 and QPI-1007 for glaucoma. Administration routes and vectors of gene drugs affect their therapeutic effect. Compared with the non-viral vectors, viral vectors have limited payload capacity and potential immunogenicity. This review summarizes the progress of the ocular siRNA gene-silencing therapy by focusing on siRNA drugs for AMD and glaucoma already used in clinical research, the main routes of drug delivery and the non-viral vectors for siRNA drugs.

Keywords

RNA interference technology; age-related macular degeneration; glaucoma; non-viral vectors; siRNA drugs.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z